Medasorb is due to release results within the next few months from a European study that measures the effectiveness of Cytosorb, the company's treatment for severe sepsis.
For months the stock was trading between six and ten cents - a ripe time for investors to accumulate - and it looks like the stock is ready to move as speculators take a position in anticipation of the results.
With a market cap of under thirteen millions - still - I expect to see the stock approach the one dollar level before the release of results, as I've indicated before. If positive, MSBT could move significantly higher seeing as there is currently no effective treatment for severe sepsis.
For those that may have missed the boat below ten cents and also missed the most recent pullback to fourteen cents, buy the dips if you're ready to speculate on the outcome of Cytosorb.
MSBT has retreated somewhat after each significant run during the recent run up, but because of the small market cap, it's tough to predict exactly where the stock will level off before pulling back again. Volume is up and the price is up, so I'd suggest that a new investor buying in pick up a few shares now in case the run continues, but leave some money on the sidelines to average down on any dips.
For those in since below ten cents, congrats and it's now time to watch the news wires; either speculators are starting to run rampant with MSBT or the word about Cytosorb is starting to get out.
If, in fact, Cytosorb is effective in treating severe sepsis, then MedaSorb (and its stock) is going to turn into one heck of a success story.
Disclosure: VFC is long MSBT.
MHTX.ob: Another stock that has spiked nicely from the five cent level of late is MHTX, the symbol for Manhattan Scientifics. I've discussed this company here before, (on a tip from Citizen Chin) mostly because of the potential of the nanotechnology that the company has acquired that can condense the matter of metals; which, in turn, reduces the weight of the metal by 25% but doubles it's strength. The sky is the limit if the company takes that technology to market.
In addition to some portable fuel cell and 3-D technology (that would add a whole new level to the on-line version of the 'Sports Illustrated Swimsuit Issue'), the company also announced on Tuesday that it is moving to acquire the rights to Rights to an Early Cancer Detection system developed by Dr. Edward R. Flynn. Dr. Flynn's technology, according to the press release, used nanomedicine and biomagnetics to detect cancer early.
The latest addition to the Manhattan Scientifics pool of licenses offers the company another potential blockbuster and if even one of them were to make it to market, then I think that the stock of this company could pay off huge.
If you're not in MHTX yet but are looking to get in, add it to the watch list and try to buy any dips.
As always, however, do your own DD first - don't just take mine or anyone else's word for it. Your money deserves your own research.
Disclosure: VFC is long MHTX.
3 COMMENTS:
Vinny,
MHTX has taken their nano metal process to market. Last month they announced a licensing deal with Carpenter Technologies (CRS), a Fortune 500 specialty metals manufacturer. MHTX will receive annual license fees (for four years) plus royalties.
Details here:
http://finance.yahoo.com/news/Manhattan-Scientifics-Inc-bw-3425818176.html?x=0&.v=1
Manhattan Scientifics, Inc. Announces Exclusive License with Carpenter Technology Corporation
LOS ALAMOS, N.M. and READING, Pa.--(BUSINESS WIRE)--Manhattan Scientifics, Inc. (OTCBB: MHTX - News) announced the signing of a contract with Carpenter Technology Corporation (NYSE: CRS - News), wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. The contract includes minimum annual payments to Manhattan Scientifics during a 4-year period, together with royalty payments as a percent of gross sales.
Manhattan Scientifics previously acquired the exclusive perpetual U.S. license to a family of patents that have been developed by scientists at the Los Alamos National Laboratory and in Russia.
The proprietary process will enable super-strength metals and alloys to make products that weigh far less than in the past and without significant cost premiums. A patented new form of titanium metal originally developed by Russian scientists, in concert with scientists at the Los Alamos National Laboratory, is expected initially to significantly improve medical prosthetics. Studies have shown that bone integrates with these new metals up to 20 times faster than with conventional metals. In December 2008, FDA approval was received for the $2 billion dental implant market. Carpenter is studying and considering other applications, including the transportation industry, where stronger, lighter metals may impact fuel economy.
“Carpenter continues to forge ahead as the leading developer of stainless steels and specialty alloys,” said Anne L. Stevens, Carpenter’s chairman and chief executive officer. “Our relationship with Manhattan Scientifics will ultimately give us new, cutting-edge manufacturing techniques that we can apply to many of our alloys to service an increasing global need for high strength materials.”
Manny Tsoupanarias, Manhattan’s CEO, said, “Carpenter Technology Corporation, a billion dollar multi-national organization, is exactly the kind of manufacturing partner we were looking for to bring our superior ultrafine grain metals to market throughout the world.” CEO Tsoupanarias continued, “The contract will provide quick and sustained revenue to Manhattan Scientifics. Moreover, we anticipate positive cash flow, reliable revenue and profitability during the next 12 months. This is a major breakthrough for our 8,600 shareholders.”
Marvin Maslow, Manhattan’s Chairman Emeritus, said, “Under Manny Tsoupanarias’s leadership, Manhattan Scientifics has re-invented itself. We have now demonstrated the efficacy of our business model by partnering with Carpenter. Manhattan’s objective has always been to identify and ‘partner’ with industrial manufacturers and marketers. The Carpenter relationship will become the tipping point to our success.”
In addressing Manhattan Scientifics, Mr. Maslow said, “We continue to be in close contact with brilliant scientists employed at the U.S. government’s multi-billion-dollar national security laboratories, who are developing disruptive, sea-change technologies. Manhattan’s goal is to show them the commercial path, provide them the capital, the courage and leadership under partnership arrangements with us. Manhattan will continue to demonstrate its ability in this respect, and plans to repeat the Carpenter-type experience with other large industrial corporations in other technical areas as it moves forward to create significant profit for its shareholders.”
Hi VFC,
Do you think if/when MHAN merges with Ariston, that they could possibly be considered a hold through Hedrin approval (if received)? In the SEC filing, it states that they will issue an additional 7 million shares if the NDA for AST-726 is accepted for filing by the FDA, and an additional ~9 million shares after that will be issued if they receive FDA approval for AST-726. So, MHAN could be looking at receiving two FDA approvals if Hedrin is approved, and if they merge with Ariston and AST-726 is approved, correct?
I'd like to hear your thoughts.
Thanks,
Noah
Dear VFC,
Would like your opinion on Antigenics (AGEN) now that oncophage has been rejected by Europe. Do you still think it has potential? Always appreciative of your time and opinion.
Thanks,
Kenneth.
Post a Comment